Skip to Content
The Big Picture San Diego Blog

AVACEN Medical

January 20, 2017

From 2025 to 2050, the 65-and-older population is projected to almost double to 1.6 billion globally, whereas the total population will grow by just 34 percent over the same period. With this, it has become increasingly important to support our aging population, with health and wellness among top priority.

San Diego medical technology company and 2016 MetroConnect participant AVACEN Medical has developed technology to help ease some of the common ailments afflicting seniors. The AVACEN 100 is an FDA cleared, over-the-counter medical device that provides non-invasive, temporary arthritis and muscle pain relief, and muscle relaxation. Using microcirculation enhancement on the palms, the locally-made device helps warm and thin the blood, thereby dissipating heat throughout deep tissues and relieving joint pain associated by arthritis, muscle spasms, sprains and more.

Taking this San Diego-made technology global, the AVACEN 100 has just received the CE (Conformité Européenne) Mark approval to treat widespread pain associated with fibromyalgia. The CE Mark allows AVACEN to market its AVACEN 100 to the European Union's 28 member countries where many prescription drugs, available in the U.S., have been rejected by regulatory officials for treating fibromyalgia pain.

Founded by Tom Muehlbauer in 2009, AVACEN’s revolutionary technology was originally developed to help alleviate his sister-in-law’s chronic pain. The company currently sells in two countries, with plans to expand into 10 more over the next year (thanks in part to the CE Mark). Sales have climbed to more than $1.5 million, with more than 20 percent of the sales coming from international markets.

July 27, 2016

This is part of a weekly series featuring a profile on one of the 2016 MetroConnect Program companies. MetroConnect is dedicated to helping local San Diego businesses go global and is presented by JPMorgan Chase.

In a recent report released by California Life Sciences Association, $23 billion in California’s 2015 exports came from life sciences. With more than 1,100 companies and a total economic impact of more than $31.8 billion, it is no surprise that San Diego’s life science sector ranks 4th in the nation. Our next MetroConnect company profile features an innovative medical device company that plans to advance San Diego’s life science reputation abroad, AVACEN Medical.

In 2009, Tom Muehlbauer founded AVACEN Medical, a company that produces a medical device initially developed for his sister-in-law who suffered from chronic migraines. Through a micro-circulation mechanism, the AVACEN 100 provides non-invasive, temporary arthritis and muscle pain relief and relaxation. Cleared by the FDA, the device is an over the counter option that’s can be self-administered from the comfort of one’s own home.

Recognizing an opportunity to expand into the EU, AVACEN Medical plans to leverage the MetroConnect Grant Prize to help in obtaining their CE mark, as well as developing better ways of delivering their products to international markets. The company also plans to use the MetroConnect Program to expand their patent portfolio, particularly across Japan, Europe and South Korea.

Muehlbauer states, “Based on the early interest and success we’ve seen in the launch of the AVACEN 100, we’re excited to scale up and bring our product to an international customer base. Arthritis and muscle pain is something that affects millions around the world, and our participation in MetroConnect will allow our at-home solution to help more of those patients in need of relief.

The success of small- and medium-sized businesses is critical to the region’s future, and increasing their global reach is crucial to that success. Through the MetroConnect Program, companies such as AVACEN Medical are to be awarded a $10,000 grant provided by JPMorgan Chase to assist with their international efforts, as well as additional support services including: a dedicated trade and investment manager at WTC San Diego to support company participants in deploying overseas strategies during the grant period; access to workshops that address export compliance, financing and fundraising and global marketing; reduced airfare on Japan Airlines direct flights from San Diego to Tokyo; free access to SYSTRAN software for website translation and customer service needs; and consideration to compete for an additional $35,000 during the MetroConnect Grand Prize Pitchfest in November 2016.